Pharmaceutical Executive conducted an in-depth Q&A with LucyRx’s Chief Commercial Officer, Susan Thomas earlier this year. Among other topics, Thomas discussed gaps in employer-sponsored GLP-1 coverage as these therapies expand beyond diabetes and weight loss. The interview explores how traditional coverage approaches can miss members with elevated cardiometabolic risk.
The five-part Q&A also highlights the challenge many employers face of expanding access while keeping costs manageable. Thomas says a more targeted approach can help plans identify higher-risk members and focus support where it can make the greatest difference.
Share